UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2018

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x

Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o

No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

This Report of Foreign Private Issuer on Form 6-K and the exhibit to this Form 6-K are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-213730 and No. 333-183143) of China Cord Blood Corporation (the “Company”)

Other Events

On January 31, 2017, the Company issued a press release announcing the consummation of a previously disclosed conditional sale agreement entered into on December 30, 2016 by and among Golden Meditech Holdings Limited, a Hong Kong listed company and a substantial shareholder of the Company (“Golden Meditech”), Golden Meditech Stem Cells (BVI) Company Limited, a wholly-owned subsidiary of Golden Meditech and Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership) (“Nanjing Ying Peng”) and the resignation of Mr. Yuen Kam (“Mr. Kam”) from the Company’s Board of Directors. The vacancy on the Board of Directors created by Mr. Kam’s resignation was filled by the appointment of Mr. Ping Xu, the authorized representative of the executive partner of Nanjing Ying Peng. Mr. Kam’s positions as Chairperson of the Company and Chairperson of the Nominating and Corporate Governance Committee (“Nominating Committee”) were filled by the appointment of Ms. Ting Zheng. Mr. Mark Chen also joined as a new member to the Nominating Committee.

A copy of the press release is attached hereto as exhibit 99.1.

Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 31, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA CORD BLOOD CORPORATION
	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer

Dated: January 31, 2018